AR011681A1 - Una composicion liofilizada que comprende trehalosa y liposomas de lipidos en los cuales se ha incorporado un principio biologicamente activo y un procedimiento para la liofilizacion de una composicion que comprende trehalosa y liposomas de lipidos - Google Patents
Una composicion liofilizada que comprende trehalosa y liposomas de lipidos en los cuales se ha incorporado un principio biologicamente activo y un procedimiento para la liofilizacion de una composicion que comprende trehalosa y liposomas de lipidosInfo
- Publication number
- AR011681A1 AR011681A1 ARP980100754A ARP980100754A AR011681A1 AR 011681 A1 AR011681 A1 AR 011681A1 AR P980100754 A ARP980100754 A AR P980100754A AR P980100754 A ARP980100754 A AR P980100754A AR 011681 A1 AR011681 A1 AR 011681A1
- Authority
- AR
- Argentina
- Prior art keywords
- liposomes
- trehalose
- biologically active
- active principle
- composition
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title abstract 9
- 239000000203 mixture Substances 0.000 title abstract 8
- 150000002632 lipids Chemical class 0.000 title abstract 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 title abstract 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 title abstract 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 title abstract 6
- 238000004108 freeze drying Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- -1 1-benzyl-1H-3-indazolyl Chemical group 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 238000001816 cooling Methods 0.000 abstract 2
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 abstract 2
- MTHORRSSURHQPZ-UHFFFAOYSA-N 2-[(1-benzylindazol-3-yl)methoxy]-2-methylpropanoic acid Chemical compound C12=CC=CC=C2C(COC(C)(C)C(O)=O)=NN1CC1=CC=CC=C1 MTHORRSSURHQPZ-UHFFFAOYSA-N 0.000 abstract 1
- 229930105110 Cyclosporin A Natural products 0.000 abstract 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
- 108010036949 Cyclosporine Proteins 0.000 abstract 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 abstract 1
- 229950009949 bindarit Drugs 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 229960001265 ciclosporin Drugs 0.000 abstract 1
- 238000007710 freezing Methods 0.000 abstract 1
- 230000008014 freezing Effects 0.000 abstract 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 abstract 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 abstract 1
- 125000005456 glyceride group Chemical group 0.000 abstract 1
- 150000002327 glycerophospholipids Chemical class 0.000 abstract 1
- 229960003538 lonidamine Drugs 0.000 abstract 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 abstract 1
- 229960003987 melatonin Drugs 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 150000003408 sphingolipids Chemical class 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97MI000362A IT1289938B1 (it) | 1997-02-20 | 1997-02-20 | Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR011681A1 true AR011681A1 (es) | 2000-08-30 |
Family
ID=11376097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980100754A AR011681A1 (es) | 1997-02-20 | 1998-02-20 | Una composicion liofilizada que comprende trehalosa y liposomas de lipidos en los cuales se ha incorporado un principio biologicamente activo y un procedimiento para la liofilizacion de una composicion que comprende trehalosa y liposomas de lipidos |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6319517B1 (enExample) |
| EP (1) | EP0981332B1 (enExample) |
| JP (1) | JP4290767B2 (enExample) |
| KR (1) | KR100496802B1 (enExample) |
| CN (1) | CN1089581C (enExample) |
| AR (1) | AR011681A1 (enExample) |
| AT (1) | ATE285754T1 (enExample) |
| AU (1) | AU744115B2 (enExample) |
| BG (1) | BG64580B1 (enExample) |
| CA (1) | CA2288958C (enExample) |
| CZ (1) | CZ295998B6 (enExample) |
| DE (1) | DE69828394T2 (enExample) |
| EA (1) | EA001637B1 (enExample) |
| ES (1) | ES2235320T3 (enExample) |
| GE (1) | GEP20022734B (enExample) |
| HU (1) | HU225593B1 (enExample) |
| IL (1) | IL131327A (enExample) |
| IT (1) | IT1289938B1 (enExample) |
| PL (1) | PL190628B1 (enExample) |
| PT (1) | PT981332E (enExample) |
| SK (1) | SK282931B6 (enExample) |
| TR (1) | TR199902025T2 (enExample) |
| UA (1) | UA70296C2 (enExample) |
| WO (1) | WO1998036736A1 (enExample) |
| ZA (1) | ZA981352B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000079283A1 (en) | 1999-06-23 | 2000-12-28 | Cornell Research Foundation, Inc. | Dehydration/rehydration of marked liposomes on a test device |
| US6576460B1 (en) | 1999-10-28 | 2003-06-10 | Cornell Research Foundation, Inc. | Filtration-detection device and method of use |
| JP2006516571A (ja) * | 2003-01-17 | 2006-07-06 | スレッシュオールド ファーマシューティカルズ， インコーポレイテッド | 良性前立腺増殖症の処置 |
| EA200702216A1 (ru) | 2005-04-12 | 2008-08-29 | Элан Фарма Интернэшнл Лимитед | Композиции в форме наночастиц с контролируемым высвобождением, содержащие циклоспорин |
| WO2008036979A2 (en) * | 2006-09-22 | 2008-03-27 | Guilford F Timothy | Topical application of melatonin directly or in liposomes for the amelioration of itching and histamine and non-histamine related inflammatory skin changes |
| CN101049504B (zh) * | 2007-04-05 | 2010-05-19 | 广州立恩生物科技有限公司 | 一种脂质体药物载体及其制备方法 |
| US9446147B2 (en) | 2011-02-24 | 2016-09-20 | The Ohio State University | Membrane stabilizing compositions and methods |
| SI2768484T1 (sl) | 2011-10-21 | 2019-12-31 | Jazz Pharmaceuticals Research Llc | Liofilizirani liposomi |
| US8999292B2 (en) | 2012-05-01 | 2015-04-07 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
| US20150224221A1 (en) * | 2012-08-31 | 2015-08-13 | Chung-Ang University Industry-Academic Cooperation Foundation | Method for preparing microspheres for emboli, and method for preparing microspheres to which drug-containing carrier is bound |
| US10722465B1 (en) | 2017-12-08 | 2020-07-28 | Quicksilber Scientific, Inc. | Transparent colloidal vitamin supplement |
| US11344497B1 (en) | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
| KR102646145B1 (ko) | 2018-05-31 | 2024-03-11 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물 |
| JP7401471B2 (ja) * | 2018-06-27 | 2023-12-19 | ブレス テラポイティクス ゲーエムベーハー | 凍結乾燥形態の医薬組成物 |
| MX2020014043A (es) * | 2018-06-27 | 2021-03-09 | Breath Therapeutics Gmbh | Composiciones inhalables que comprenden inmunosupresores macrociclicos. |
| CN112261871B (zh) | 2018-07-28 | 2022-05-17 | 韩国外泌体生技有限公司 | 用于使外排体冻干的方法 |
| KR102163806B1 (ko) | 2018-07-30 | 2020-10-07 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물 |
| EA202092892A1 (ru) | 2018-12-04 | 2021-05-27 | Брес Терапьютикс Гмбх | Ингаляционные композиции, содержащие макроциклические иммуносупрессанты |
| US11291702B1 (en) | 2019-04-15 | 2022-04-05 | Quicksilver Scientific, Inc. | Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method |
| US11753382B2 (en) | 2019-06-25 | 2023-09-12 | Translatum Medicus Inc. | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives |
| CN111358955B (zh) * | 2020-04-01 | 2023-05-02 | 重庆理工大学 | 一种用于治疗脂质代谢疾病的炎症靶向的宾达利纳米粒、制备方法及其应用 |
| JP7508359B2 (ja) * | 2020-12-11 | 2024-07-01 | 株式会社東芝 | 脂質粒子の製造方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1173360A (en) * | 1979-06-22 | 1984-08-28 | Jurg Schrank | Pharmaceutical preparations |
| FR2542749B1 (fr) * | 1983-03-18 | 1985-07-12 | Beghin Say Sa | Copolymere allyloligosaccharide-acrylique salifie, procede de preparation du copolymere et application comme super-absorbant |
| US4857319A (en) * | 1985-01-11 | 1989-08-15 | The Regents Of The University Of California | Method for preserving liposomes |
| US4963362A (en) * | 1987-08-07 | 1990-10-16 | Regents Of The University Of Minnesota | Freeze-dried liposome mixture containing cyclosporin |
| US5683714A (en) * | 1991-04-19 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Liposomal cyclosporin pharmaceutical formulation |
| US5817336A (en) * | 1993-04-02 | 1998-10-06 | Orion-Yhtyma Oy | Composition containing selegiline |
| GB9320668D0 (en) * | 1993-10-07 | 1993-11-24 | Secr Defence | Liposomes containing particulare materials |
| EP0678017B1 (en) * | 1993-11-05 | 1998-04-01 | Amgen Inc. | Liposome preparation and material encapsulation method |
-
1997
- 1997-02-20 IT IT97MI000362A patent/IT1289938B1/it active IP Right Grant
-
1998
- 1998-02-12 AU AU64969/98A patent/AU744115B2/en not_active Ceased
- 1998-02-12 AT AT98910659T patent/ATE285754T1/de active
- 1998-02-12 IL IL13132798A patent/IL131327A/en not_active IP Right Cessation
- 1998-02-12 JP JP53622898A patent/JP4290767B2/ja not_active Expired - Fee Related
- 1998-02-12 WO PCT/EP1998/000817 patent/WO1998036736A1/en not_active Ceased
- 1998-02-12 US US09/367,715 patent/US6319517B1/en not_active Expired - Lifetime
- 1998-02-12 SK SK1110-99A patent/SK282931B6/sk not_active IP Right Cessation
- 1998-02-12 PT PT98910659T patent/PT981332E/pt unknown
- 1998-02-12 DE DE69828394T patent/DE69828394T2/de not_active Expired - Lifetime
- 1998-02-12 TR TR1999/02025T patent/TR199902025T2/xx unknown
- 1998-02-12 CZ CZ19992925A patent/CZ295998B6/cs not_active IP Right Cessation
- 1998-02-12 PL PL98335207A patent/PL190628B1/pl unknown
- 1998-02-12 EA EA199900751A patent/EA001637B1/ru not_active IP Right Cessation
- 1998-02-12 CN CN98802737A patent/CN1089581C/zh not_active Expired - Fee Related
- 1998-02-12 GE GEAP19984991A patent/GEP20022734B/en unknown
- 1998-02-12 HU HU0001464A patent/HU225593B1/hu not_active IP Right Cessation
- 1998-02-12 ES ES98910659T patent/ES2235320T3/es not_active Expired - Lifetime
- 1998-02-12 KR KR10-1999-7007538A patent/KR100496802B1/ko not_active Expired - Fee Related
- 1998-02-12 EP EP98910659A patent/EP0981332B1/en not_active Expired - Lifetime
- 1998-02-12 CA CA002288958A patent/CA2288958C/en not_active Expired - Fee Related
- 1998-02-18 ZA ZA981352A patent/ZA981352B/xx unknown
- 1998-02-20 AR ARP980100754A patent/AR011681A1/es active IP Right Grant
- 1998-12-02 UA UA99095150A patent/UA70296C2/uk unknown
-
1999
- 1999-09-16 BG BG103738A patent/BG64580B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR011681A1 (es) | Una composicion liofilizada que comprende trehalosa y liposomas de lipidos en los cuales se ha incorporado un principio biologicamente activo y un procedimiento para la liofilizacion de una composicion que comprende trehalosa y liposomas de lipidos | |
| US7939098B2 (en) | Compositions and method for transmucosal drug delivery and cryoprotection | |
| EP0691852B1 (en) | Valproic acid covalently bonded to a lysophospholipid | |
| ES2221066T3 (es) | Utilizacion de inhibidores de no-sintasa y de eliminadores de formas reactivas del oxigeno para el tratamiento de la isquemia. | |
| AR023971A1 (es) | Derivados de 4,5,6,7-tetrahidroindazol, procedimiento para la preparacion de los mismos y su utilizacion como agentes antitumorales | |
| CO5130023A1 (es) | Administracion de agente activo en polvo seco agente activo y un inhibidor del crecimiento higroscopico | |
| ES2280355T3 (es) | Sistema de administracion de medicamentos basados en lipidos para su utilizacion en la piel. | |
| BR0015567A (pt) | Compostos de ácido fenoxicarboxìlico e composições para liberar agentes ativos | |
| ATE286718T1 (de) | Temperatursensitive liposomale formulierung | |
| CO5261556A1 (es) | Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico | |
| ES2232302B1 (es) | Myo-inositol hexafosfato para uso topico. | |
| PE20050822A1 (es) | Derivados de florfenicol con mejor solubilidad en agua | |
| PT93884B (pt) | Processo de preparacao de uma composicao farmaceutica a base de acido 5-amino-salicilico, sob a forma de uma espuma | |
| CR6643A (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
| CA2401498A1 (en) | New self emulsifying drug delivery system | |
| ES2171923T3 (es) | Profarmacos de la talidomida, su procedimiento de preparacion y su utilizacion como principios activos en medicamentos. | |
| MX9301197A (es) | Derivados de indol. | |
| CO4940406A1 (es) | Composiciones de paracetamol de accion rapida | |
| AR020226A1 (es) | Compuestos para la inhibicion de la secrecion de acido gastrico, procesos para su preparacion, formulaciones farmaceuticas y uso de dichos compuestos parapreparar medicamentos | |
| AR033151A1 (es) | Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares | |
| ES2716806T3 (es) | Formulación Oftálmica | |
| DE60042831D1 (de) | Pharmazeutisch aktive sulfonylaminosäurederivate | |
| PA8613001A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina | |
| WO1998041213A1 (en) | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof | |
| ES2213894T3 (es) | Composicion farmaceutica acuosa que comprende un principio activo que es altamente insoluble en agua. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FG | Grant, registration |